Sarepta Therapeutics (SRPT) versus The Competition Head-To-Head Survey
Sarepta Therapeutics (NASDAQ: SRPT) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Sarepta Therapeutics to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends.
Earnings & Valuation
This table compares Sarepta Therapeutics and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sarepta Therapeutics||$5.42 million||-$267.26 million||-25.66|
|Sarepta Therapeutics Competitors||$284.30 million||$34.29 million||129.99|
Insider and Institutional Ownership
82.0% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 9.6% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Sarepta Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sarepta Therapeutics Competitors||-5,355.33%||-433.53%||-38.99%|
This is a breakdown of recent recommendations for Sarepta Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sarepta Therapeutics Competitors||845||3193||11580||230||2.71|
Sarepta Therapeutics currently has a consensus price target of $66.11, indicating a potential upside of 26.28%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.62%. Given Sarepta Therapeutics’ rivals higher possible upside, analysts plainly believe Sarepta Therapeutics has less favorable growth aspects than its rivals.
Volatility & Risk
Sarepta Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics’ rivals have a beta of 1.80, meaning that their average share price is 80% more volatile than the S&P 500.
Sarepta Therapeutics rivals beat Sarepta Therapeutics on 7 of the 12 factors compared.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.
Receive News & Stock Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related stocks with our FREE daily email newsletter.